Dr. Jean H. Siedel
Claim this profileUniversity of Michigan Comprehensive Cancer Center
Studies Adenocarcinoma
Studies Serous Cystadenocarcinoma
8 reported clinical trials
22 drugs studied
Area of expertise
1Adenocarcinoma
Stage IV
Stage III
Stage II
2Serous Cystadenocarcinoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Jean H. Siedel is currently running
Ipatasertib + Megestrol Acetate
for Endometrial Cancer
This trial is testing if combining two drugs, ipatasertib and megestrol acetate, is more effective than using megestrol acetate alone for treating women with endometrial cancer that has returned or spread. Ipatasertib blocks enzymes needed for cancer cell growth, while megestrol acetate reduces and blocks estrogen, which some cancer cells need to grow.
Recruiting1 award Phase 1 & 2
Letrozole +/- Chemotherapy
for Ovarian Cancer
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving letrozole alone or in combination with paclitaxel and carboplatin works better in treating patients with low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum compared to paclitaxel and carboplatin without letrozole.
Recruiting2 awards Phase 318 criteria
More about Jean H. Siedel
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jean H. Siedel has experience with
- Carboplatin
- Paclitaxel
- Olaparib
- Cediranib Maleate
- Durvalumab
- Letrozole
Breakdown of trials Jean H. Siedel has run
Adenocarcinoma
Serous Cystadenocarcinoma
Endometrioid Carcinoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jean H. Siedel specialize in?
Jean H. Siedel focuses on Adenocarcinoma and Serous Cystadenocarcinoma. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Jean H. Siedel currently recruiting for clinical trials?
Yes, Jean H. Siedel is currently recruiting for 3 clinical trials in Ann Arbor Michigan. If you're interested in participating, you should apply.
Are there any treatments that Jean H. Siedel has studied deeply?
Yes, Jean H. Siedel has studied treatments such as Carboplatin, Paclitaxel, Olaparib.
What is the best way to schedule an appointment with Jean H. Siedel?
Apply for one of the trials that Jean H. Siedel is conducting.
What is the office address of Jean H. Siedel?
The office of Jean H. Siedel is located at: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States. This is the address for their practice at the University of Michigan Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.